Christopher C. Gallen
Algemeen Directeur bij Treos Bio Ltd.
Oorsprong van het eerstegraads netwerk van Christopher C. Gallen
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Neuromed Pharmaceuticals Ltd.
 Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC.
11
| Extinct | Pharmaceuticals: Major | 11 |
CombinatoRx, Inc.
 CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA
11
| Extinct | Pharmaceuticals: Other | 11 |
Neuromed Pharmaceuticals, Inc.
 Neuromed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals, Inc. develops new and improved pain medicines. It has multiple programs aimed at addressing this important unmet medical need. Its lead product candidate, ExalgoTM is an extended release formulation of hydromorphone in phase 3 clinical development. Neuromed is also developing oral drug candidates to block N-type and T-type calcium channels, an important target directly involved in pain signaling, and includes candidates for potentially treating pain, epilepsy and hypertension.
7
| Extinct | Pharmaceuticals: Major | 7 |
Treos Bio Ltd.
 Treos Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Treos Bio Ltd. engages in the development of a digital cancer vaccine technology platform that provides tailored precision vaccines to patients. It focuses on cancer immunotherapies. The company was founded by john Kenneth Hautman and Julianna Lisziewicz in 2013 and is headquartered in London, the United Kingdom.
6
| Holding Company | Miscellaneous Commercial Services | 6 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Christopher C. Gallen via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
Wyeth Holdings LLC
 Wyeth Holdings LLC Chemicals: AgriculturalProcess Industries Wyeth Holdings LLC manufactures and distributes chemicals. The firm's chemical contains phosphate rock, calcium, lime, carbide and nitrogen which are used in fertilizers. The company was founded by Frank Washburn in 1907 and is headquartered in Wayne, NJ. | Chemicals: Agricultural | Corporate Officer/Principal | |
Wyeth Corp.
 Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
SICOR, Inc.
 SICOR, Inc. Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Angiotech Pharmaceuticals, Inc.
 Angiotech Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, which engages in developing, manufacturing and marketing medical products and technologies, within the areas of interventional oncology, wound closure and ophthalmology. The company was founded by William L. Hunter and Cruz F. Tony in 1992 and is headquartered in Vancouver, Canada. | Medical Specialties | Director/Board Member Chief Executive Officer Sales & Marketing | |
Coley Pharmaceutical Group, Inc.
 Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
| CORREVIO PHARMA CORP. | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer | |
| RESPONSE BIOMEDICAL CORP | Miscellaneous Commercial Services | Director of Finance/CFO | |
| INMED PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
| SHIRE | Pharmaceuticals: Major | Corporate Officer/Principal | |
| WAVE LIFE SCIENCES LTD. | Biotechnology | Director/Board Member | |
| University of Virginia | College/University | Doctorate Degree Graduate Degree | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor | |
| Dartmouth College | College/University | Undergraduate Degree Masters Business Admin | |
| Boston University | College/University | Graduate Degree Masters Business Admin | |
| ALLON THERAPEUTICS INC. | Pharmaceuticals: Major | Chairman | |
| University of British Columbia | College/University | Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal | |
| Simon Fraser University | College/University | Doctorate Degree Undergraduate Degree | |
| University of Western Ontario | College/University | Doctorate Degree Undergraduate Degree | |
Nabriva Therapeutics GmbH
 Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | Director/Board Member | |
Richardson Capital Ltd.
 Richardson Capital Ltd. Investment ManagersFinance Richardson Capital Ltd. (Richardson Capital) is a private equity arm of Richardson Financial Group Ltd founded in 2003. The firm is headquartered in Winnipeg, Canada. | Investment Managers | Chief Investment Officer Corporate Officer/Principal | |
NDI Capital, Inc.
 NDI Capital, Inc. Investment ManagersFinance NDI Capital, Inc (NDI Capital) is a venture capital firm Founded in 2003 and headquartered in Vancouver, British Columbia. | Investment Managers | Chief Executive Officer | |
| AMAG PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| Gateway Income Trust | Director/Board Member | ||
Marex Group PLC
 Marex Group PLC Internet Software/ServicesTechnology Services Marex Group Plc provides brokerage services for commodities, financials, and foreign exchange. It operates through Clearing, Agency and Execution, Market Making, and Hedging and Investment Solutions segments. The Clearing segment allows the clients access to exchanges and clearing houses. The Agency and Execution segment match buyers and sellers on an agency basis by facilitating price discovery of commodities and financial markets. The Market Making segment offers direct market pricing to professional and wholesale counterparties in a variety of commodity and securities markets. The company was founded by Mark Slade in 2005 and is headquartered in London, the United Kingdom. | Internet Software/Services | Director/Board Member Director/Board Member | |
Silver Creek Pharmaceuticals, Inc.
 Silver Creek Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Silver Creek Pharmaceuticals, Inc. develops novel regenerative medicines. The firm focuses on treating cardiovascular disease. Its molecules are designed to promote resilience and regeneration of damaged tissues after acute or chronic injury. The company was founded in 2010 and is headquartered in San Francisco, CA. | Pharmaceuticals: Major | President | |
| The University of Chicago Booth School of Business | College/University | Masters Business Admin | |
| EPIRUS BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Perseus Holdings USA LLC
 Perseus Holdings USA LLC Electronics DistributorsDistribution Services Perseus Holdings USA LLC markets vaccine platform technology. The company is headquartered in Austin, TX. | Electronics Distributors | Director/Board Member | |
| School of Pharmacy (CONNECTICUT) | College/University | Undergraduate Degree | |
| NABRIVA THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
Tremeau Pharmaceuticals, Inc.
 Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA. | Pharmaceuticals: Major | Chief Executive Officer | |
Exacis Biotherapeutics, Inc.
 Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | Medical/Nursing Services | Chairman |
Statistieken
Internationaal
| Verenigde Staten | 25 |
| Canada | 21 |
| Verenigd Koninkrijk | 3 |
| Ierland | 3 |
| Singapore | 2 |
Sectoraal
| Health Technology | 29 |
| Consumer Services | 10 |
| Commercial Services | 5 |
| Finance | 4 |
| Process Industries | 2 |
Operationeel
| Director/Board Member | 212 |
| Corporate Officer/Principal | 58 |
| Independent Dir/Board Member | 44 |
| Chairman | 35 |
| Chief Executive Officer | 23 |
Sterkste connecties
| Insiders | |
|---|---|
| Todd Foley | 38 |
| Mark Corrigan | 29 |
| Kurt C. Wheeler | 28 |
| Ruth Alon | 27 |
| Hartley Richardson | 26 |
| Robert M. Forrester | 25 |
| Peter Kadas | 25 |
| Sally Crawford | 22 |
| Bill Hunter | 22 |
| Jim J. Miller | 19 |
| Richard Pops | 17 |
| Frank W. Haydu | 16 |
| Bruce Colwill | 15 |
| Barbara H. Deptula | 12 |
| Jason Cole | 10 |
- Beurs
- Insiders
- Christopher C. Gallen
- Bedrijfsconnecties